参麦注射液对中晚期肺癌化疗患者血清前白蛋白的影响  

作　　者：谢小妹[1] 张一帆[1] 李向阳[1] 郭永忠[1] 

机构地区：[1]江苏省徐州市中心医院,221009

出　　处：《浙江临床医学》2016年第8期1410-1411,共2页Zhejiang Clinical Medical Journal

基　　金：江苏省徐州市中心医院博士（硕士）创新团队科技基金资助项目（xzs2013024）;江苏省徐州市科技局基金项目（XZZD1345）

摘　　要：目的观察参麦注射液对中晚期肺癌化疗患者血清前白蛋白（PA）的影响。方法102例肺癌患者，随机分为观察组（参麦注射液联合化疗）和对照组（单纯化疗），每组各5l例。观察两组胃肠道反应、治疗前后血清PA水平及KPs评分变化。结果观察组胃肠道反应发生率为52．94％，明显低于对照组的74，51％（P=O．023）；治疗后观察组PA水平为（25．06±18．58）mg／L，明显高于对照组的（-0．98±13．94）mg／L（p：0．011）；观察组KPs评分稳定率为86．27％，高于对照组的68．63％（P=0．041）。结论参麦注射液可改善中晚期肺癌化疗患者的营养状况。Objective To evaluate the effect of Shenmai injection on serum prealbumin （ PA ） level in patients with advanced lung cancer receiving chemotherapy. Method 102 advanced lung cancer patients were randomly assigned to observation group （ Shenmai injection plus routine chemotherapy ） and control group （ routine chemotherapy ） .The gastrointestinal toxicity, the changes of serum PA and KPS pre- and post-treatment between the two groups were observed. Results The incidence of gastrointestinal toxicity, the changes of PA level and the stable rate of KPS score were 52.94% vs. 74.51% （ P=0.023 ） , （ 25.06 ±18.58 ） mg/L vs. （ -0.98 ± 13.94 ） mg/L （ P=0.011 ） and 86.27% vs. 68.63% （ P=0.041 ） in the observation and control groups, respectively. Conclusion Shenmai injection can improve the nutritional status in patients with advanced lung cancer receiving chemotherapy. [ Key words ] Shenmai injection Lung cancer Chemotherapy Prealbumin

关 键 词：参麦注射液 肺癌 化疗 前白蛋白 

分 类 号：R259.414[医药卫生—中西医结合]